Fluorocytidine derivatives and COX-2 inhibitors for the treatment of cancer
View Patent ↗The present invention provides, in certain embodiments, methods for the treatment of colorectal cancer comprising administering a COX-2 inhibitor and fluorocytidine derivative to a human patient. In certain embodiments, a radiation therapy is also administered to the patient.
1. A method for treating cancer in a human patient comprising administering an effective amount of celecoxib and capecitabine to the patient, wherein the cancer is a nodal metastasis of a metastatic colorectal cancer.
2. The method of claim 1 , wherein the nodal metastasis is a solitary nodal metastasis.
3. The method of claim 1 , wherein the nodal metastasis is a clustered nodal metastasis.
4. The method of claim 1 , wherein the patient has not been previously treated for the cancer.
5. The method of claim 1 , wherein the patient has been previously treated for the cancer.
6. The method of claim 5 , wherein the previous treatment comprised administration of irinotecan to the patient.
7. The method of claim 5 , wherein the previous treatment comprised administration of surgery to the patient.
8. The method of claim 1 , wherein the method further comprises administration of a second cancer therapy to the patient.
9. The method of claim 8 , wherein the second cancer therapy is a chemotherapeutic, an anti-cancer drug, a surgical therapy, or a radiation therapy.
10. The method of claim 9 , wherein the second cancer therapy is a radiation therapy.
11. The method of claim 10 , wherein the radiation therapy comprises administration of from about 25 to about 65 Gy of radiation to the patient.
12. The method of claim 11 , wherein the radiation therapy comprises administration of from about 35 to about 50 Gy of radiation to the patient.
13. The method of claim 12 , wherein the radiation therapy comprises administration of from about 35 to about 45 Gy of radiation to the patient.
14. The method of claim 13 , wherein the radiation therapy comprises a 3-D conformal planning technique.
15. The method of claim 1 , wherein the method reduces the probability of capecitabine-induced hand-foot syndrome in the patient.
16. The method of claim 1 , wherein the fluorocytidine derivative is administered orally.
17. The method of claim 16 , wherein the fluorocytidine derivative is administered at a dose of from about 850 to about 1300 mg/m 2 /d.
18. The method of claim 16 , wherein the fluorocytidine derivative is administered at a dose of from about 900 to about 1250 mg/m 2 /d.
19. The method of claim 16 , wherein the fluorocytidine derivative is administered at a dose of about 1000 mg/m 2 /d.
20. The method of claim 1 , wherein the COX-2 inhibitor is administered at a dose of about 200 mg b.i.d.